🇺🇸 FDA
Patent

US 8795656

Methods of treating rheumatoid arthritis by administering an anti-IL3 antibody

granted A61KA61K2039/505A61K38/00

Quick answer

US patent 8795656 (Methods of treating rheumatoid arthritis by administering an anti-IL3 antibody) held by Klinikum der Universität Regensburg expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Klinikum der Universität Regensburg
Grant date
Tue Aug 05 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61K38/00, A61P, A61P19/02